Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Leukemia, Myeloid, Chronic-Phase (CML-CP)”

103 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 103 results

Testing effectiveness (Phase 2)Study completedNCT01744665
What this trial is testing

A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation

Who this might be right for
CML
Novartis Pharmaceuticals 59
Large-scale testing (Phase 3)UnknownNCT03942094
What this trial is testing

Nilotinib for First-line Newly Diagnosed CML-CP Patients

Who this might be right for
Chronic Myeloid Leukemia, Chronic PhaseNilotinib
Shenzhen Second People's Hospital 100
Not applicableStudy completedNCT07374120
What this trial is testing

Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting

Who this might be right for
Leukemia, Myeloid, Chronic-Phase
Novartis Pharmaceuticals 1,480
Post-approval studies (Phase 4)Study completedNCT01660906
What this trial is testing

Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib

Who this might be right for
Chronic Phase Chronic Myeloid Leukemia
Bristol-Myers Squibb 39
Large-scale testing (Phase 3)Ended earlyNCT02627677
What this trial is testing

A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia

Who this might be right for
Chronic Phase Chronic Myeloid Leukemia
Ariad Pharmaceuticals 44
Testing effectiveness (Phase 2)Looking for participantsNCT06514534
What this trial is testing

Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.

Who this might be right for
Chronic Myeloid Leukemia (CML)
Novartis Pharmaceuticals 20
Testing effectiveness (Phase 2)UnknownNCT02422719
What this trial is testing

Radotinib as 3rd or Later Line Therapy in CP-CML

Who this might be right for
Chronic Myeloid Leukemia
Ulsan University Hospital 73
Large-scale testing (Phase 3)Study completedNCT01511289
What this trial is testing

Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients

Who this might be right for
LeukemiaLeukemia, MyeloidLeukemia, Myelogenous, Chronic, BCR-ABL Positive+3 more
Il-Yang Pharm. Co., Ltd. 242
Testing effectiveness (Phase 2)Study completedNCT00072579
What this trial is testing

Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment

Who this might be right for
Leukemia
Wake Forest University Health Sciences
Large-scale testing (Phase 3)Study completedNCT04666259
What this trial is testing

Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation

Who this might be right for
Chronic Myelogenous Leukemia - Chronic Phase
Novartis Pharmaceuticals 56
Testing effectiveness (Phase 2)UnknownNCT01627132
What this trial is testing

Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial

Who this might be right for
Chronic Myeloid Leukemia
Shimousa Hematology Study Group 50
Post-approval studies (Phase 4)Study completedNCT01735955
What this trial is testing

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Who this might be right for
Chronic Myelogenous Leukemia (CML)Metastatic Gastrointestinal Stromal Tumors (GIST)Acute Lymphoblastic Leukemia (ALL)+1 more
Novartis Pharmaceuticals 57
Large-scale testing (Phase 3)Study completedNCT00471497
What this trial is testing

Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Who this might be right for
Myelogenous Leukemia, Chronic
Novartis Pharmaceuticals 846
Testing effectiveness (Phase 2)UnknownNCT01802450
What this trial is testing

Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

Who this might be right for
Chronic Myeloid Leukemia
PETHEMA Foundation 18
Testing effectiveness (Phase 2)Looking for participantsNCT04925479
What this trial is testing

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Who this might be right for
Myeloid Leukemia, Philadelphia Positive
Novartis Pharmaceuticals 34
Post-approval studies (Phase 4)Study completedNCT01043874
What this trial is testing

Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response

Who this might be right for
Philadelphia Chromosome PositiveChronic Myelogenous Leukemia in Chronic Phase
Novartis Pharmaceuticals 45
Large-scale testing (Phase 3)Not Yet RecruitingNCT07489755
What this trial is testing

TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients

Who this might be right for
Chronic Myelogenous LeukemiaChronic Myelogenous Leukemia - Chronic Phase
Shenzhen TargetRx Co., Ltd. 180
Testing effectiveness (Phase 2)Study completedNCT01698905
What this trial is testing

Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

Who this might be right for
Chronic Myeloid Leukemia
Novartis Pharmaceuticals 163
Early research (Phase 1)Study completedNCT01702064
What this trial is testing

Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients

Who this might be right for
Chronic Phase Chronic Myeloid Leukemia
H. Lee Moffitt Cancer Center and Research Institute 11
Not applicableNo Longer AvailableNCT04518644
What this trial is testing

Nilotinib, for Patients With CML-CP or CML-AP

Who this might be right for
Chronic Myelogenous Leukemia (CML)
Novartis Pharmaceuticals
Next Page